Multiple sclerosis presents as an exceptionally heterogeneous neuroinflammatory and neurodegenerative disorder. Clinicians have long recognized that the rate of long-term disability accumulation differs significantly among individual patients. While conventional clinical wisdom historically tied disease worsening directly to recurrent inflammatory demyelinating plaques, emerging genomic analyses challenge this paradigm. Recent integrative genomic models now identify distinct patient clusters that follow markedly divergent disability trajectories. Understanding the biological foundations of multiple sclerosis severity requires correlating these genomic profiles with postmortem neuropathological alterations. A landmark multi-center investigation has provided crucial insights into this relationship by demonstrating a striking uncoupling between genomic disability drivers and classic inflammatory lesion burdens. Consequently, these findings reshape our understanding of disease progression, therapeutic monitoring, and individualized neuroprotective strategies in modern neurological practice.

Deciphering Genetic Drivers of Multiple Sclerosis Severity

Historically, genome-wide association studies focused predominantly on disease susceptibility loci, which are heavily enriched in adaptive immunity genes. However, genetic determinants of multiple sclerosis severity appear biologically distinct from susceptibility markers. Researchers recently stratified patients into distinct genomic clusters based on multidimensional severity scores. To determine whether these severity clusters reflect specific tissue-level damage, investigators analyzed clinical, genetic, and postmortem neuropathological datasets from 291 brain donors archived in the UK MS Society Tissue Bank. Specifically, donors in genomic cluster 2 exhibited significantly worse clinical outcomes, characterized by a lower age-adjusted disease duration score and a shorter interval from progression onset to death compared to clusters 1 and 3. Nevertheless, this accelerated disability trajectory occurred without a corresponding increase in acute focal demyelinating events. Therefore, genomic determinants of aggressive disease appear to operate through mechanisms beyond typical focal inflammatory destruction.

Neuropathological Stratification in the UK MS Tissue Bank

The postmortem cohort provided an unprecedented opportunity to evaluate neuropathological features across well-defined genomic strata. Neuropathologists systematically characterized lesion types, distinguishing between active, chronic active, and chronic inactive demyelinating plaques across cerebral hemispheres. Furthermore, the analysis incorporated quantitative immunohistochemistry to measure microglial activation and major histocompatibility complex expression. Donors assigned to cluster 1 exhibited a higher frequency of chronic active broad-rim lesions compared to clusters 2 and 3. In contrast, donors within clusters 2 and 3 displayed an enrichment of chronic inactive lesions. Consequently, the neuropathological phenotype demonstrated substantial qualitative variation across genetic clusters. Moreover, these observations confirm that patients experiencing more rapid functional decline do not necessarily harbor larger quantities of chronic active rim lesions. Instead, alternate pathways of cellular injury likely drive tissue loss in severe genetic subgroups.

Uncoupling Disability Trajectories from Inflammatory Lesion Burden

The central revelation of this neuropathological investigation is the clear dissociation between clinical worsening and focal lesion pathology. Clinicians frequently encounter progression independent of relapse activity, commonly termed PIRA. This study provides direct histological validation for this clinical phenomenon. Patients in the adverse genomic cluster accumulated severe neurological impairment despite presenting with predominantly chronic inactive lesions rather than actively expanding inflammatory rims. Furthermore, statistical modeling confirmed that focal inflammatory lesion burden does not account for the accelerated interval to mortality seen in cluster 2. Thus, neurodegeneration in progressive multiple sclerosis proceeds independently of localized perivascular cuffing or peripheral lymphocytic infiltration. Additionally, these results suggest that diffuse axonal injury, metabolic failure, and intrinsic glial dysfunction serve as primary drivers of long-term functional decline in genetically vulnerable individuals.

HLA Genetic Background and Microglial Activation Patterns

The human leukocyte antigen locus remains the strongest genetic contributor to disease risk and local inflammatory responses. In this cohort, donors categorized into cluster 1 carried the highest cumulative HLA genetic burden. Notably, this pronounced HLA background strongly correlated with heightened non-lesional HLA-D immunoreactivity throughout normal-appearing white matter. Furthermore, transcriptome profiling revealed significant elevations in HLA-DRB1 and HLA-DRB5 messenger RNA expression within this group. These high-HLA donors demonstrated a greater abundance of both classic active lesions and chronic active broad-rim lesions. Conversely, individuals with lower HLA burdens showed fewer active plaques but experienced equally or more severe clinical progression. Therefore, while HLA-driven immunity governs localized rim activity and diffuse microglial antigen presentation, it does not exclusively dictate the rate of clinical neurodegeneration. This critical distinction explains why highly effective anti-inflammatory therapies often fail to halt insidious disease progression.

Clinical Implications for Progression Independent of Relapse Activity

These neuropathological insights carry profound implications for contemporary clinical management and future clinical trial design. Current disease-modifying therapies primarily target peripheral immune cell trafficking and adaptive inflammatory responses. While these therapies successfully suppress relapses and new magnetic resonance imaging lesions, they often show limited efficacy against progressive disability accumulation. Consequently, practicing neurologists must recognize that a low burden of active enhancing lesions does not guarantee protection against progressive neurodegeneration. Moreover, biomarker development must expand beyond focal lesion counts to capture diffuse axonal loss and compartmentalized central nervous system pathology. Moving forward, clinical trials should incorporate genomic stratification to identify individuals at high risk for rapid progression. Ultimately, developing targeted neuroprotective and remyelinating compounds tailored to specific genetic subtypes will be essential to halt irreversible disability in multiple sclerosis.

How do genetic subtypes influence multiple sclerosis progression independently of lesions?

Genetic subtypes affect neurodegenerative pathways and diffuse microglial activation throughout normal-appearing brain tissue. Consequently, patients with adverse genomic clusters experience rapid disability progression without developing a higher burden of focal demyelinating lesions. This divergence suggests distinct cellular mechanisms drive neurodegeneration and chronic focal inflammation in multiple sclerosis.

What role does the HLA complex play in multiple sclerosis tissue pathology?

The HLA genetic background strongly correlates with chronic active broad-rim lesions and widespread microglial activation. Individuals harboring heavy HLA genetic burdens display elevated non-lesional HLA-D immunoreactivity alongside increased HLA-DRB1 expression. However, these distinct immune signatures do not uniformly correlate with the overall rate of clinical disability accumulation.

How does this genetic uncoupling change current treatment approaches for multiple sclerosis?

Current disease-modifying therapies predominantly target peripheral focal inflammatory activity rather than compartmentalized neurodegeneration. Because disability trajectories diverge from lesion load, clinicians must recognize that suppressing relapses may not arrest progression. Future therapeutic strategies must therefore integrate neuroprotective agents specifically tailored to an individual's underlying genetic risk profile.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Refer to the latest local and national guidelines for clinical practice.

References

Abbadessa G et al. Genetic subtypes of multiple sclerosis severity are uncoupled from inflammatory lesion burden. Acta Neuropathol. 2026 Aug 21. doi: 10.1007/s00401-026-03062-x. PMID: 42627512.

International Multiple Sclerosis Genetics Consortium. Locus for severity implicates CNS resilience in progression of multiple sclerosis. Nature. 2023;619(7969):323-331.

Kappos L et al. Progression independent of relapse activity in multiple sclerosis: defining the next therapeutic frontier. Lancet Neurol. 2020;19(9):748-759.

Absinta M et al. Association of chronic active multiple sclerosis lesions with disability in vivo. JAMA Neurol. 2019;76(12):1474-1483.